title: Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors.
authors.affiliation: Clinical Pharmacy Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. lucasokumura@yahoo.com.br.
authors.forename: Lucas Miyake
authors.identifier: http://orcid.org/0000-0003-3607-619X
authors.initials: LM
authors.lastname: Okumura
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D003907:Dexamethasone / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D009325:Nausea / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists / Q000627:therapeutic use*; D017294:Ondansetron / Q000009:adverse effects*; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000627:therapeutic use*; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D058831:Serotonin 5-HT3 Receptor Antagonists; D017294:Ondansetron; D003907:Dexamethasone